Paper41233352
Oligomeric cystatin C supports the immunosuppressive activity of myeloid cells through interaction with inhibitory receptors.
Zhang C and 14 others. Signal Transduct Target Ther, 2025. Cited by 1 paper, by iCite.
Cite this record
ConductScience Library. Oligomeric cystatin C supports the immunosuppressive activity of myeloid cells through interaction with inhibitory receptors. Papers, record 41233352. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/41233352
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics10
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Cystatin C | Major topic |
| Receptors, Immunologic | Major topic |
| Myeloid Cells | Major topic |
| Membrane Glycoproteins | Major topic |
| Animals | |
| Humans | |
| Mice | |
| Mice, Transgenic | |
| Tumor Microenvironment | |
| Signal Transduction |
Source PubMed
Grants11
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by | Source |
|---|---|---|---|---|---|
| R01 CA263079 | NCI NIH HHS | United States | R01CA263079 | PubMed and NIH | NIH RePORTER |
| R01CA263079 | Division of Cancer Prevention, National Cancer Institute (NCI Division of Cancer Prevention) | R01CA263079 | PubMed and NIH | NIH RePORTER | |
| RP190561 | Cancer Prevention and Research Institute of Texas (Cancer Prevention Research Institute of Texas) | PubMed | PubMed | ||
| R01CA248736 | Division of Cancer Prevention, National Cancer Institute (NCI Division of Cancer Prevention) | R01CA248736 | PubMed and NIH | NIH RePORTER | |
| RP15150551 | Cancer Prevention and Research Institute of Texas (Cancer Prevention Research Institute of Texas) | PubMed | PubMed | ||
| P30 CA142543 | NCI NIH HHS | United States | P30CA142543 | PubMed and NIH | NIH RePORTER |
| AU-0042-20030616 | Welch Foundation | PubMed | PubMed | ||
| Lung Cancer SPORE Development Research Program | Division of Cancer Prevention, National Cancer Institute (NCI Division of Cancer Prevention) | PubMed | PubMed | ||
| RP220032 | Cancer Prevention and Research Institute of Texas (Cancer Prevention Research Institute of Texas) | PubMed | PubMed | ||
| 5P30CA142543 | Division of Cancer Prevention, National Cancer Institute (NCI Division of Cancer Prevention) | P30CA142543 | PubMed and NIH | NIH RePORTER | |
| R01 CA248736 | NCI NIH HHS | United States | R01CA248736 | PubMed and NIH | NIH RePORTER |
References82
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 17718592 | Molecular dynamics simulations of human cystatin C and its L68Q varient to investigate the domain swapping mechanism. | J Biomol Struct Dyn | 2007 | https://conductscience.org/library/papers/17718592 | PubMed |
| 2 | 35218869 | Transthyretin: Its function and amyloid formation. | Neurochem Int | 2022 | https://conductscience.org/library/papers/35218869 | PubMed |
| 3 | 36747021 | Therapeutic targeting of tumour myeloid cells. | Nat Rev Cancer | 2023 | https://conductscience.org/library/papers/36747021 | PubMed |
| 4 | 11276250 | Human cystatin C, an amyloidogenic protein, dimerizes through three-dimensional domain swapping. | Nat Struct Biol | 2001 | https://conductscience.org/library/papers/11276250 | PubMed |
| 5 | 33974041 | LILRB4 suppresses immunity in solid tumors and is a potential target for immunotherapy. | J Exp Med | 2021 | https://conductscience.org/library/papers/33974041 | PubMed |
| 6 | 36564420 | Association of plasma cystatin C with all-cause and cause-specific mortality among middle-aged and elderly individuals: a prospective community-based cohort study. | Sci Rep | 2022 | https://conductscience.org/library/papers/36564420 | PubMed |
| 7 | 25817520 | Frequency and profile of Parkinson's disease prodromi in patients with malignant melanoma. | J Neurol Neurosurg Psychiatry | 2016 | https://conductscience.org/library/papers/25817520 | PubMed |
| 8 | 35262173 | Melanoma-Secreted Amyloid Beta Suppresses Neuroinflammation and Promotes Brain Metastasis. | Cancer Discov | 2022 | https://conductscience.org/library/papers/35262173 | PubMed |
| 9 | 26040207 | Functional and genetic diversity of leukocyte immunoglobulin-like receptor and implication for disease associations. | J Hum Genet | 2015 | https://conductscience.org/library/papers/26040207 | PubMed |
| 10 | 30352428 | Blocking immunoinhibitory receptor LILRB2 reprograms tumor-associated myeloid cells and promotes antitumor immunity. | J Clin Invest | 2018 | https://conductscience.org/library/papers/30352428 | PubMed |
| 11 | 14534577 | Smad-dependent and Smad-independent pathways in TGF-beta family signalling. | Nature | 2003 | https://conductscience.org/library/papers/14534577 | PubMed |
| 12 | 22378262 | Tafamidis. | Nat Rev Drug Discov | 2012 | https://conductscience.org/library/papers/22378262 | PubMed |
| 13 | 15037657 | Cystatin C antagonizes transforming growth factor beta signaling in normal and cancer cells. | Mol Cancer Res | 2004 | https://conductscience.org/library/papers/15037657 | PubMed |
| 14 | 23661553 | TGF-β signaling in myeloid cells is required for tumor metastasis. | Cancer Discov | 2013 | https://conductscience.org/library/papers/23661553 | PubMed |
| 15 | 25491510 | Amyloid-β precursor protein promotes cell proliferation and motility of advanced breast cancer. | BMC Cancer | 2014 | https://conductscience.org/library/papers/25491510 | PubMed |
| 16 | 10748866 | Decreased metastatic spread in mice homozygous for a null allele of the cystatin C protease inhibitor gene. | Mol Pathol | 1999 | https://conductscience.org/library/papers/10748866 | PubMed |
| 17 | 28498720 | Protein Misfolding, Amyloid Formation, and Human Disease: A Summary of Progress Over the Last Decade. | Annu Rev Biochem | 2017 | https://conductscience.org/library/papers/28498720 | PubMed |
| 18 | 20194151 | Clinical features and treatment response of light chain (AL) amyloidosis diagnosed in patients with previous diagnosis of multiple myeloma. | Mayo Clin Proc | 2010 | https://conductscience.org/library/papers/20194151 | PubMed |
| 19 | 36658726 | Cancer Cells Enter an Adaptive Persistence to Survive Radiotherapy and Repopulate Tumor. | Adv Sci (Weinh) | 2023 | https://conductscience.org/library/papers/36658726 | PubMed |
| 20 | 10835680 | Receptor-dependent cell stress and amyloid accumulation in systemic amyloidosis. | Nat Med | 2000 | https://conductscience.org/library/papers/10835680 | PubMed |
Cited by2
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 1 citation.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42958587 | Beyond conventional immune checkpoints: the LILRB axis as a dual regulator of tumor and immune cell states. | J Exp Clin Cancer Res | 2026 | https://conductscience.org/library/papers/42958587 | PubMed |
| 42242571 | Frailty phenotype, genetic risk and long-term incident systemic lupus erythematosus risk: Insights from the UK Biobank study integrated with multi-omics analysis. | Clin Med (Lond) | 2026 | https://conductscience.org/library/papers/42242571 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/41233352
GET https://conductscience.org/api/papers/v1/41233352/references?page=2